Drug Interaction Report

GENERALLY AVOID: Coadministration with potent or moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of capmatinib. According to the prescribing information, capmatinib is primarily metabolized by CYP450 3A4 and aldehyde oxidase. When administered with rifampin, a potent CYP450 3A4 inducer, capmatinib peak plasma concentration (Cmax) and systemic exposure (AUC) decreased by 56% and 67%, respectively. Coadministration with efavirenz, a moderate CYP450 3A4 inducer, decreased capmatinib Cmax and AUC by 34% and 44%, respectively. Loss of anti-tumor activity may result.

MANAGEMENT: Concomitant use of capmatinib with potent or moderate CYP450 3A4 inducers should be avoided.